MedTrace Logo

The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

NCT07602803 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this observational study is to learn about the long-term effects of GLP1 agonists (weight loss jab, including Mounjaro) in our patients with Bardet-Biedl Syndrome (BBS) who take GLP1 agonists to treat their high body weight. The main question:

Do GLP1 agonists effectively and safely lower body weight in patients with BBS when taken long-term, compared to patients not on these medications? We look at the change (%) in weight during the observational periods.

Conditions

  • Barded-Biedl Syndrome

Sponsors & Collaborators

  • The Queen Elizabeth Hospital

    lead OTHER

Principal Investigators

  • Jeremy Tomlinson, Professor · University Hospital Birmingham NHS Foundation Trust

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-04-01
Completion
2026-04-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07602803 on ClinicalTrials.gov